Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for IGC Pharma Inc. (IGC:NYSE), powered by AI.
IGC Pharma Inc. is currently trading at $0.28. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for IGC Pharma Inc. on Alpha Lenz.
IGC Pharma Inc.'s P/E ratio is -3.0.
“IGC Pharma Inc. trades at a P/E of -3.0 (undervalued) with modest ROE of -104.3%. 3Y revenue CAGR of 47.4% highlights clear growth momentum.”
Ask for details →IGC Pharma Inc. is a pharmaceutical and biotechnology company focused on the development and commercialization of innovative therapies for the treatment of chronic pain, cancer, and other life-altering conditions. The company's primary role involves leveraging unique approaches to drug development, particularly using cannabinoids, to create novel solutions that address unmet medical needs. IGC Pharma operates within the biotech sector, which is marked by significant research and development activities and a robust pipeline of products at various stages of clinical trials. Notably, IGC Pharma's initiatives in the pharmaceutical industry aim at integrating traditional pharmaceutical methods with new advancements in cannabinoid science. This positions the company as a potential influencer in sectors such as pain management and oncology, where treatment options are continually evolving. Due to its focus on strategic research and development, IGC Pharma plays a crucial role in the broader biotechnology market, aiming to introduce cutting-edge therapies that can change the standard of care for complex medical conditions.
“IGC Pharma Inc. trades at a P/E of -3.0 (undervalued) with modest ROE of -104.3%. 3Y revenue CAGR of 47.4% highlights clear growth momentum.”
Ask for details →IGC Pharma Inc. (ticker: IGC) is a company listed on NYSE in the Healthcare sector (Biotechnology). It has approximately 70 employees. Market cap is $21M.
The current price is $0.278 with a P/E ratio of -2.98x and P/B of 3.36x.
ROE is -104.33% and operating margin is -585.84%. Annual revenue is $1M.